EWM
SCLN

Evercore Wealth Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Evercore Wealth Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-8,000
Closed -$40K – 1021
2013
Q2 		$40K Buy
+8,000
New +$38.1K ﹤0.01% 593

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Evercore Wealth Management's SCLN Position: Q3 2013 in Review

Evercore Wealth Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2013, closing a stake of 8,000 shares — an estimated $40K sold.

Evercore Wealth Management first reported a position in SCLN in Q2 2013 and held it in 1 quarter. The position peaked at $40K in Q2 2013. 102 funds tracked by Wall St. Rank hold SCLN as of Q3 2013.

  • Evercore Wealth Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Evercore Wealth Management sold 8,000 Sciclone Pharmaceuticals Inc shares in Q3 2013, an estimated $40K.
  • Evercore Wealth Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Evercore Wealth Management's Sciclone Pharmaceuticals Inc position peaked at $40K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2013.

Based on Evercore Wealth Management's 13F filing for Q3 2013, filed 13 Nov 2013.